SYRE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SYRE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Spyre Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -1,867.49%.
As of today (2024-05-11), Spyre Therapeutics's WACC % is 27.24%. Spyre Therapeutics's ROIC % is -269.44% (calculated using TTM income statement data). Spyre Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
The historical data trend for Spyre Therapeutics's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
ROIC % | Get a 7-Day Free Trial | -967.01 | -560.10 | -374.41 | -501.38 | -1,212.17 |
Spyre Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
ROIC % | Get a 7-Day Free Trial | -504.64 | -554.64 | -113.26 | -129.61 | -1,867.49 |
For the Biotechnology subindustry, Spyre Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's ROIC % distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's ROIC % falls into.
Spyre Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:
ROIC % (A: Dec. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (A: Dec. 2022 ) | + | Invested Capital (A: Dec. 2023 )) | / count ) |
= | -128.564 * ( 1 - 0.01% ) | / | ( (14.947 | + | 6.263) | / 2 ) |
= | -128.5511436 | / | 10.605 | |||
= | -1,212.17 % |
where
Invested Capital | (A: Dec. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 71.144 | - | 8.595 | - | ( 55.711 | - | max(0, 14.656 | - | 62.258 | + | 55.711 | )) |
= | 14.947 |
Invested Capital | (A: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 341.859 | - | 26.046 | - | ( 339.277 | - | max(0, 31.978 | - | 341.528 | + | 339.277 | )) |
= | 6.263 |
Spyre Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:
ROIC % (Q: Dec. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2023 ) | + | Invested Capital (Q: Dec. 2023 )) | / count ) |
= | -191.016 * ( 1 - 0% ) | / | ( (14.194 | + | 6.263) | / 2 ) |
= | -191.016 | / | 10.2285 | |||
= | -1,867.49 % |
where
Invested Capital | (Q: Sep. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 207.265 | - | 31.994 | - | ( 203.599 | - | max(0, 44.872 | - | 205.949 | + | 203.599 | )) |
= | 14.194 |
Invested Capital | (Q: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 341.859 | - | 26.046 | - | ( 339.277 | - | max(0, 31.978 | - | 341.528 | + | 339.277 | )) |
= | 6.263 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (NAS:SYRE) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Spyre Therapeutics's WACC % is 27.24%. Spyre Therapeutics's ROIC % is -269.44% (calculated using TTM income statement data).
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Thank you for viewing the detailed overview of Spyre Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott L Burrows | officer: Chief Financial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Heidy King-jones | officer: See Remarks | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Fairmount Healthcare Co-invest L.p. | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Peter Evan Harwin | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Funds Management Llc | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Cameron Turtle | officer: Chief Operating Officer | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104 |
Michael Thomas Henderson | director | 421 KIPLING STREET, PALO ALTO CA 94301 |
Fairmount Healthcare Fund L.p. | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Healthcare Fund Ii L.p. | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Tomas Kiselak | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Jeff Marc Goldberg | director, officer: President and CEO | C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142 |
Linda L Neuman | officer: Chief Medical Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746 |
Marcio Souza | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
James Paul Kastenmayer | officer: Interim CEO & General Counsel | ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879 |
Hanley Jr. Michael Conick | officer: Chief Commercial Officer | C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746 |
From GuruFocus
By PRNewswire • 12-08-2023
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire PRNewswire • 04-12-2023
By PRNewswire PRNewswire • 10-19-2022
By PRNewswire • 09-14-2023
By PRNewswire PRNewswire • 11-30-2022
By PRNewswire • 12-22-2023
By PRNewswire PRNewswire • 08-24-2022
By PRNewswire PRNewswire • 08-19-2022
By PRNewswire PRNewswire • 11-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.